
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Brand Name | Status | Last Update |
|---|---|---|
| adlarity | New Drug Application | 2023-02-17 |
| aricept | New Drug Application | 2022-11-15 |
| donepezil | ANDA | 2025-09-30 |
| donepezil donepezil hydrochloride | ANDA | 2019-10-09 |
| donepezil hydrochloride | ANDA | 2025-08-21 |
| donepezil hydrochloride donepezil hyrochloride | ANDA | 2019-01-09 |
| memantine and donepezil | ANDA | 2025-07-10 |
| memantine and donepezil hydrochlorides | ANDA | 2025-01-01 |
| memantine and donepezil hydrochlorides extended-release | ANDA | 2025-02-06 |
| memantine hydrochloride and donepezil hydrochloride | ANDA | 2025-06-20 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alzheimer disease | EFO_0000249 | D000544 | F03 |
Expiration | Code | ||
|---|---|---|---|
DONEPEZIL HYDROCHLORIDE, ADLARITY, CORIUM | |||
| 2025-03-11 | NP | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Donepezil Hydrochloride, Adlarity, Corium | |||
| 10966936 | 2038-08-11 | DP | U-3334 |
| 10835499 | 2038-05-20 | DP | U-3334 |
| 11648214 | 2037-09-23 | DP | U-3334 |
| 9993466 | 2037-07-26 | DP | |
| 10016372 | 2037-07-26 | U-3334 | |
| 10300025 | 2037-07-26 | DP | |
| 10307379 | 2037-07-26 | DP | |
| 11103463 | 2037-07-26 | U-3334 | |
| 11679086 | 2037-05-26 | U-3334 | |
| Donepezil Hydrochloride / Memantine Hydrochloride, Namzaric, Abbvie | |||
| 8058291 | 2029-12-05 | U-1641 | |
| 8039009 | 2029-03-24 | U-1641 | |
| 8168209 | 2025-11-22 | DP | |
| 8173708 | 2025-11-22 | U-1641 | |
| 8283379 | 2025-11-22 | U-1641 | |
| 8293794 | 2025-11-22 | DP | |
| 8329752 | 2025-11-22 | DP | |
| 8338485 | 2025-11-22 | DP | |
| 8338486 | 2025-11-22 | U-1641 | |
| 8362085 | 2025-11-22 | U-1641 | |
| 8580858 | 2025-11-22 | U-1641 | |
| 8598233 | 2025-11-22 | DP | |
| Donepezil Hydrochloride, Aricept, Eisai Inc | |||
| 8481565 | 2026-10-04 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 2 | — | — | — | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 2 | — | — | — | 2 |
| Drug common name | Donepezil |
| INN | donepezil |
| Description | Donepezil is a racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor, a nootropic agent and an EC 3.1.1.8 (cholinesterase) inhibitor. It contains a (R)-donepezil and a (S)-donepezil. It is a conjugate base of a donepezil (1+). |
| Classification | Small molecule |
| Drug class | acetylcholinesterase inhibitors used in the treatment of Alzheimer's disease |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 |
| PDB | — |
| CAS-ID | 120014-06-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL502 |
| ChEBI ID | 53289 |
| PubChem CID | 3152 |
| DrugBank | DB00843 |
| UNII ID | 8SSC91326P (ChemIDplus, GSRS) |












